Neoplasms, Germ Cell and Embryonal
Information
- Disease name
- Neoplasms, Germ Cell and Embryonal
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04222972 | Active, not recruiting | Phase 3 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | July 24, 2020 | June 30, 2025 |
| NCT03911388 | Active, not recruiting | Phase 1 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | September 12, 2019 | September 1, 2026 |
| NCT05592743 | Available | Vorasidenib Expanded Access Program | |||
| NCT02863003 | Completed | Multicenter Database of Patients With Germ Cell Tumor | September 2016 | December 2020 | |
| NCT03012620 | Completed | Phase 2 | Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | July 5, 2017 | December 14, 2023 |
| NCT00393861 | Completed | Phase 2 | Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients | October 2006 | November 2014 |
| NCT03403777 | Completed | Phase 2 | Avelumab in Refractory Testicular Germ Cell Cancer. | November 15, 2017 | February 28, 2019 |
| NCT03037385 | Completed | Phase 1/Phase 2 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | March 17, 2017 | March 21, 2024 |
| NCT00611962 | Completed | Phase 2 | Phase II Study of Oxaliplatine-Paclitaxel in Patients With Metastatic Germ Cell Tumor Refractory to Cisplatin | December 2000 | March 2004 |
| NCT02679950 | Completed | Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse | November 20, 2015 | April 25, 2017 | |
| NCT04657315 | Completed | Phase 1/Phase 2 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients | June 24, 2020 | December 22, 2022 |
| NCT04949282 | Recruiting | Spanish Series of Patients Treated With the Radionuclide Lutetium177 | May 10, 2021 | December 31, 2035 | |
| NCT02859415 | Terminated | Phase 1/Phase 2 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | August 8, 2019 | December 1, 2021 |
| NCT02533765 | Unknown status | Phase 2 | Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor | September 11, 2015 | June 2021 |
| NCT04697446 | Unknown status | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC | December 1, 2020 | October 31, 2021 | |
| NCT02839694 | Withdrawn | Phase 1 | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | July 7, 2016 | April 26, 2017 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009373